John Oyler: BeOne Medicines reports positive results for BCL2 inhibitor in cancer study

John Oyler: BeOne Medicines reports positive results for BCL2 inhibitor in cancer study
@johnvoyler: BeOne reports positive cancer study

BeOne Medicines, led by CEO John Oyler, has announced encouraging topline results from its Phase 2 study. The trial focused on their next-generation BCL2 inhibitor, a promising treatment for patients with relapsed or refractory mantle cell lymphoma.

This development represents a significant advancement for patients facing this challenging form of cancer. Oyler stated that the company remains committed to ''advancing science for patients'' and emphasized the importance of this milestone in the fight against difficult cancers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.